Abstract 1896P
Background
Management of cancer patients at the ED has long been problematic, especially with regard to the intensity of care for patients near the end of life. We sought to investigate the utility of MO consultation at the ED in indicating the best supportive care for cancer patients.
Methods
Consecutive MO consultations with patients presented to the ED from January 1 to March 31, 2024 were recorded. MO indication of best supportive care (BSC) was correlated with overall survival (OS) and 30-day mortality rate (30-DMR). Additionally, 47 clinical and laboratory candidate variables were collected and correlated with OS. Significant variables (p ≤0.005) selected at univariate analysis were analyzed in a multivariate Cox-regression model.
Results
Out of 10,896 adult ED visits, MO consultation was required in 120 visits (1.1% of cases) well below the 5% prevalence of cancer patient ED visits reported in the literature). The most common cancers for which consultation was required were lung, gastrointestinal, and genitourinary cancer, and most common presenting symptoms were pain (25%), dyspnea (25%), and neurological symptoms (19%). Following MO consultation, BSC was indicated in 47.8% of cases. BSC indication was associated to a significantly higher 30-DMR compared to active treatment indication: 25% vs 13%, HR 3.01 (95%CI: 1.34 to 6.71), p 0.007. Following univariate analysis, alkaline phosphatase (ALP), neutrophils-to-lymphocyte ratio, Charlson comorbidity index, concomitant infection and modified Glasgow prognostic score (mGPS) were selected for the multivariate model and ALP >100 IU/L (HR 5.28, 95%CI: 1.73-16.12, p 0.003) and mGPS score 2 (HR 12.78, 95%CI: 2.89-56.53, p 0.0008) were confirmed to be independent predictors of OS. Among patients eligible to active treatment, those with ALP>100 and/or mGPS=2 had a 30-DMR of 22% vs 6% of patients with ALP<100 and mGPS 0/1.
Conclusions
Early MO consultation is strongly recommended for the appropriate management of cancer patients in the Emergency Room. ALP and mGPS may assist prognostication in this setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1950P - Squamous cell carcinoma of unknown primary (SCCUP): A genomic landscape study
Presenter: Hannah Robinson
Session: Poster session 12
1951P - A multicenter, retrospective study of non-small-cell lung carcinoma (NSCLC) harboring EGFR exon 20 insertions: Distribution, variants, and prevalence of coalterations
Presenter: Ivana Gabriela Sullivan
Session: Poster session 12
1952P - Multiomic spatial profiling of whole-slide NSCLC tissues from patients receiving anti PD-1 therapy identifies metabolic phenotypes associated with therapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 12
1953P - The ATXN3-USP25-TRMT1 axis regulates tRNAm2,2G modification and promotes osimertinib resistance in lung cancer
Presenter: Tianqing Chu
Session: Poster session 12
Resources:
Abstract